Aesthetic medicine of the new generation

M1 Akademie

In-house training and development is a key element of the M1 Group's business model. That is why M1 operates the M1 Akademie. The main topics of the training courses provided are new treatment procedures, innovations and product presentations in the fields of aesthetic medicine as well as plastic and aesthetic surgery. Due to this uniform training and further education of all doctors and medical staff, M1 is able to offer customers the highest quality regardless of location.

M1 Akademie at a glance:

  • Worldwide private training centre for physicians, specialists and dentists
  • Neueste Behandlungsverfahren, Innovationen und
  • Latest treatment procedures, innovations and product presentations for the areas:
    • Aesthetic medicine
    • Plastic and aesthetic surgery
  • Providing practical experience, different techniques and detailed complication management
  • Brain pool with many years of know-how
  • Represented in Germany, Austria, Switzerland, the Netherlands, UK, Croatia, Hungary and Australia

We provide quality, techniques and expertise to doctors

More about M1 Akademie

Latest news

Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasing and sales, which he was previously responsible for together with Co-CEO Attila Strauss, will in future be managed by Attila Strauss alone.

In the first quarter of 2024, the M1 Group increased its consolidated sales by 9.6% from EUR 76.8 million to EUR 84.7 million. In comparison, operating earnings before interest and taxes (EBIT) increased at a disproportionately high rate. M1 improved Group EBIT by 70% from EUR 4.0 million to EUR 6.8 million. The Group EBIT margin increased accordingly from 5.3% to 8.1%.

| Investor News

  • Group sales increase by 10.9% to € 316.3 million in 2023
  • Highly profitable beauty segment drives growth with an increase of 17.6% to EUR 70.8 million
  • Consolidated net profit (after minority interests) improved from EUR 4.3 million to EUR 10.3 million
  • Dividend proposal of EUR 0.50 per share
  • Medium-term forecast for the Beauty segment: target sales of EUR 200 to 300 million by 2029 with an EBIT margin of at least 20%

| Ad-hoc news

The Supervisory Board of M1 Kliniken AG (ISIN:DE000A0STSQ8) today approved the annual financial statements and the consolidated financial the annual financial statements and the consolidated financial statements of the financial year 2023 presented by the Management Board in accordance with Sections 171, 172 AktG. The annual financial statements are thus adopted in accordance with Section 172 AktG.